Following previously described treatment algorithms49, anti-PD-1 (Murine IgG2a clone RMP1-14, BioXcell®) monoclonal antibody was administered on day 3, 6, and 9 post tumor inoculation (Fig. 6a, Schema). This evidence concerns the gene PDCD1 and neoplasm.